放射治疗局部进展胰腺癌的研究进展

王希海; 赵相轩; 卢再鸣; 郭启勇

doi:10.3969/j.issn.1001-5256.2017.11.045

放射治疗局部进展胰腺癌的研究进展

DOI: 10.3969/j.issn.1001-5256.2017.11.045

中国医科大学附属盛京医院放射科

基金项目:

国家自然基金资助项目(31371425)；国家自然科学基金资助项目(31240025)；

详细信息

中图分类号: R730.55;R735.9
计量
- 文章访问数: 1282
- HTML全文浏览量: 29
- PDF下载量: 393
- 被引次数: 0
出版历程
- 收稿日期: 2017-06-18
- 出版日期: 2017-11-20

Research advances in radiotherapy for locally advanced pancreatic cancer

Department of the Radiology, Shengjing Hospital of China Medical University

Research funding:

摘要

摘要: 局部进展胰腺癌的预后较差,传统放射治疗、传统放射治疗联合化学药物治疗对局部进展胰腺的局部控制及生存获益有限。立体定向放射治疗和调强放射治疗能够控制局部肿瘤进展,改善患者生存质量,且不良反应相对较少,近年在局部进展胰腺癌中逐步应用。抑制DNA修复药物发展迅速,DNA修复抑制剂联合放射治疗在分子、细胞、动物水平经广泛研究,并已初步在临床应用,能够有效改善局部进展胰腺癌的预后。
- 胰腺肿瘤 /
- 放射外科 /
- 手术立体定位技术 /
- 放射疗法,调强适形 /
- 综述
Abstract: Locally advanced pancreatic cancer has a poor prognosis, and conventional radiotherapy alone or combined with chemotherapy has limited effects on local control of locally advanced pancreatic cancer and survival benefit for such patients.Stereotactic radiotherapy and intensity-modulated radiotherapy can control local tumor progression and improve patients' quality of life with few adverse effects and have gradually been used in the treatment of locally advanced pancreatic cancer in recent years.Rapid development of drugs inhibiting DNA repair and extensive research on DNA repair inhibitors at the molecular, cellular, and animal levels and their preliminary clinical application can effectively improve the prognosis of locally advanced pancreatic cancer.
- pancreatic neoplasms /
- radiosurgery /
- stereotaxic techniques /
- radiotherapy, intensity-modulated /
- review

HTML全文

参考文献(48)

[1]GILLEN S, SCHUSTER T, MEYER ZUM BUSCHENFELDE C, et al.Preoperative/neoadjuvant therapy in pancreatic cancer:a systematic review and meta-analysis of response and resection percentages[J].PLo S Med, 2010, 7 (4) :e1000267.

[2]COMBS SE, HABERMEHL D, WERNER J, et al.Strategies for preoperative downsizing in patients with local nonresectable pancreatic cancer[J].Chirurg, 2011, 82 (11) :981-988.

[3]LI D, XIE K, WOLFF R, et al.Pancreatic cancer[J].Lancet, 2004, 363 (9414) :1049-1057.

[4]IACOBUZIO-DONAHUE CA, FU B, YACHIDA S, et al.DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer[J].J Clin Oncol, 2009, 27 (11) :1806-1813.

[5]COMBS SE, GANSWINDT U, FOOTE RL, et al.State-of-the-art treatment alternatives for base of skull meningiomas:complementing and controversial indications for neurosurgery, stereotactic and robotic based radiosurgery or modern fractionated radiation techniques[J].Radiat Oncol, 2012, 7:226.

[6]COMBS SE, ADEBERG S, DITTMAR JO, et al.Skull base meningiomas:long-term results and patient self-reported outcome in507 patients treated with fractionated stereotactic radiotherapy (FS-RT) or intensity modulated radiotherapy (IMRT) [J].Radiother Oncol, 2013, 106 (2) :186-191.

[7]COMBS SE, WELZEL T, SCHULZ-ERTNER D, et al.Differences in clinical results after LINAC-based single-dose radiosurgery versus fractionated stereotactic radiotherapy for patients with vestibular schwannomas[J].Int J Radiat Oncol Biol Phys, 2010, 76 (1) :193-200.

[8]SCHEFTER TE, KAVANAGH BD, TIMMERMAN RD, et al.Aphase I trial of stereotactic body radiation therapy (SBRT) for liver metastases[J].Int J Radiat Oncol Biol Phys, 2005, 62 (5) :1371-1378.

[9]CHANG JY, ROTH JA.Stereotactic body radiation therapy for stage Inon-small cell lung cancer[J].Thorac Surg Clin, 2007, 17 (2) :251-259.

[10]CUNHA MV, AL-OMAIR A, ATENAFU EG, et al.Vertebral compression fracture (VCF) after spine stereotactic body radiation therapy (SBRT) :analysis of predictive factors[J].Int J Radiat Oncol Biol Phys, 2012, 84 (3) :e343-e349.

[11]SHAIB WL, HAWK N, CASSIDY RJ, et al.A Phase 1 study of stereotactic body radiation therapy dose escalation for borderline resectable pancreatic cancer after modified FOLFIRINOX (NCT01446458) [J].Int J Radiat Oncol Biol Phys, 2016, 96 (2) :296-303.

[12]LANGEN KM, JONES DT.Organ motion and its management[J].Int J Radiat Oncol Biol Phys, 2001, 50 (1) :265-278.

[13]HEERKENS HD, van VULPEN M, van den BERG CA, et al.MRI-based tumor motion characterization and gating schemes for radiation therapy of pancreatic cancer[J].Radiother Oncol, 2014, 111 (2) :252-257.

[14]YANG W, FRAASS BA, REZNIK R, et al.Adequacy of inhale/exhale breathhold CT based ITV margins and image-guided registration for free-breathing pancreas and liver SBRT[J].Radiat Oncol, 2014, 9:11.

[15]HUGUET F, YORKE ED, DAVIDSON M, et al.Modeling pancreatic tumor motion using 4-dimensional computed tomography and surrogate markers[J].Int J Radiat Oncol Biol Phys, 2015, 91 (3) :579-587.

[16]TANIGUCHI CM, MURPHY JD, ECLOV N, et al.Dosimetric analysis of organs at risk during expiratory gating in stereotactic body radiation therapy for pancreatic cancer[J].Int J Radiat Oncol Biol Phys, 2013, 85 (4) :1090-1095.

[17]CUI Y, SONG J, POLLOM E, et al.Quantitative Analysis of (18) F-fluorodeoxyglucose positron emission tomography identifies novel prognostic imaging biomarkers in locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy[J].Int JRadiat Oncol Biol Phys, 2016, 96 (1) :102-109.

[18]SCHELLENBERG D, QUON A, MINN AY, et al.18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy[J].Int J Radiat Oncol Biol Phys, 2010, 77 (5) :1420-1425.

[19]DHOLAKIA AS, CHAUDHRY M, LEAL JP, et al.Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy[J].Int J Radiat Oncol Biol Phys, 2014, 89 (3) :539-546.

[20]KOONG AC, LE QT, HO A, et al.Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer[J].Int J Radiat Oncol Biol Phys, 2004, 58 (4) :1017-1021.

[21]KOONG AC, CHRISTOFFERSON E, LE QT, et al.Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer[J].Int J Radiat Oncol Biol Phys, 2005, 63 (2) :320-323.

[22]SCHELLENBERG D, GOODMAN KA, LEE F, et al.Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer[J].Int J Radiat Oncol Biol Phys, 2008, 72 (3) :678-686.

[23]HOYER M, ROED H, SENGELOV L, et al.Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma[J].Radiother Oncol, 2005, 76 (1) :48-53.

[24]POLISTINA F, COSTANTIN G, CASAMASSIMA F, et al.Unresectable locally advanced pancreatic cancer:a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration[J].Ann Surg Oncol, 2010, 17 (8) :2092-2101.

[25]COMITO T, COZZI L, CLERICI E, et al.Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma?results of a phase 2 study[J].Technol Cancer Res Treat, 2017, 16 (3) :295-301.

[26]MONINGI S, MARCISCANO AE, ROSATI LM, et al.Stereotactic body radiation therapy in pancreatic cancer:the new frontier[J].Expert Rev Anticancer Ther, 2014, 14 (12) :1461-1475.

[27]GKIKA E, ADEBAHR S, KIRSTE S, et al.Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer:a toxicity review of simultaneous integrated protection (SIP) versus conventional SBRT[J].Strahlenther Onkol, 2017, 193 (6) :433-443.

[28]GURKA MK, COLLINS SP, SLACK R, et al.Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer:a pilot trial demonstrating safety[J].Radiat Oncol, 2013, 8:44.

[29]LISCHALK JW, BURKE A, CHEW J, et al.Five-fraction stereotactic body radiation therapy (SBRT) and chemotherapy for the local management of metastatic pancreatic cancer[J].J Gastrointest Cancer, 2017.[Epub ahead of print]

[30]ROSATI LM, HERMAN JM.Role of stereotactic body radiotherapy in the treatment of elderly and poor performance status patients with pancreatic cancer[J].J Oncol Pract, 2017, 13 (3) :157-166.

[31]NAKAMURA A, SHIBUYA K, NAKAMURA M, et al.Interfractional dose variations in the stomach and the bowels during breathhold intensity-modulated radiotherapy for pancreatic cancer:implications for a dose-escalation strategy[J].Med Phys, 2013, 40 (2) :021701.

[32]SANGALLI G, PASSONI P, CATTANEO GM, et al.Planning design of locally advanced pancreatic carcinoma using 4DCT and IM-RT/IGRT technologies[J].Acta Oncol, 2011, 50 (1) :72-80.

[33]ABELSON JA, MURPHY JD, MINN AY, et al.Intensity-modulated radiotherapy for pancreatic adenocarcinoma[J].Int J Radiat Oncol Biol Phys, 2012, 82 (4) :e595-e601.

[34]SON SH, SONG JH, CHOI BO, et al.The technical feasibility of an image-guided intensity-modulated radiotherapy (IG-IMRT) to perform a hypofractionated schedule in terms of toxicity and local control for patients with locally advanced or recurrent pancreatic cancer[J].Radiat Oncol, 2012, 7:203.

[35]BEN-JOSEF E, SCHIPPER M, FRANCIS IR, et al.A phase I/IItrial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer[J].Int J Radiat Oncol Biol Phys, 2012, 84 (5) :1166-1171.

[36]WANG Z, REN ZG, MA NY, et al.Intensity modulated radiotherapy for locally advanced and metastatic pancreatic cancer:a monoinstitutional retrospective analysis[J].Radiat Oncol, 2015, 10:14.

[37]LIN JC, JEN YM, LI MH, et al.Comparing outcomes of stereotactic body radiotherapy with intensity-modulated radiotherapy for patients with locally advanced unresectable pancreatic cancer[J].Eur J Gastroenterol Hepatol, 2015, 27 (3) :259-264.

[38]HAMMEL P, HUGUET F, van LAETHEM JL, et al.Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib:the LAP07 randomized clinical trial[J].JAMA, 2016, 315 (17) :1844-1853.

[39]SCHREIBER V, DANTZER F, AME JC, et al.Poly (ADP-ribose) :novel functions for an old molecule[J].Nat Rev Mol Cell Biol, 2006, 7 (7) :517-528.

[40]TULI R, SURMAK AJ, REYES J, et al.Radiosensitization of pancreatic cancer cells in vitro and in vivo through poly (ADP-ribose) polymerase inhibition with ABT-888[J].Transl Oncol, 2014.[Epub ahead of print]

[41]REAPER PM, GRIFFITHS MR, LONG JM, et al.Selective killing of ATM-or p53-deficient cancer cells through inhibition of ATR[J].Nat Chem Biol, 2011, 7 (7) :428-430.

[42]FOKAS E, PREVO R, POLLARD JR, et al.Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation[J].Cell Death Dis, 2012, 3:e441.

[43]VANCE S, LIU E, ZHAO L, et al.Selective radiosensitization of p53mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1[J].Cell Cycle, 2011, 10 (24) :4321-4329.

[44]ENGELKE CG, PARSELS LA, QIAN Y, et al.Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776[J].Clin Cancer Res, 2013, 19 (16) :4412-4421.

[45]KAUSAR T, SCHREIBER JS, KARNAK D, et al.Sensitization of pancreatic cancers to gemcitabine chemoradiation by WEE1 kinase inhibition depends on homologous recombination repair[J].Neoplasia, 2015, 17 (10) :757-766.

[46]CHUNG V, MANSFIELD AS, BRAITEH F, et al.Safety, tolerability, and preliminary activity of LB-100, an inhibitor of protein phosphatase2A, in patients with relapsed solid tumors:an open-label, dose escalation, first-in-human, phase I trial[J].Clin Cancer Res, 2016, 23 (13) :3277-3284.

[47]WEI D, PARSELS LA, KARNAK D, et al.Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repair[J].Clin Cancer Res, 2013, 19 (16) :4422-4432.

[48]LI YH, WANG X, PAN Y, et al.Inhibition of non-homologous end joining repair impairs pancreatic cancer growth and enhances radiation response[J].PLo S One, 2012, 7 (6) :e39588.

施引文献

资源附件(0)

访问统计